Tevogen Bio Stock Quote TVGN - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

0.98

Bid

0.98

Ask

1.00

Volume

10,793,065

0.9311 Day's Range 1.20

0.803 52 Week Range 21.09

Market Cap

165.421M

Previous Close

0.85

Open

1.20

Last Trade

462

0.98

(formt)

Last Trade Time

Financial Volume

$ 10,987,118

VWAP

1.018

Average Volume (3m)

468,745

Shares Outstanding

165,421,084

Dividend Yield

PE Ratio

37.59

Earnings Per Share (EPS)

0.03

Revenue

Net Profit

4.41M

Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.

Sector

Blank Checks

Industry

Blank Checks

Website

www.tevogen.com/

Headquarters

Wilmington, Delaware, USA

Founded

1970

Tevogen Bio Holdings Inc is listed in the Blank Checks sector of the NASDAQ with ticker TVGN. The last closing price for Tevogen Bio was $0.85. Over the last year, Tevogen Bio shares have traded in a share price range of $ 0.803 to $ 21.09.

Tevogen Bio currently has 165,421,084 shares outstanding. The market capitalization of Tevogen Bio is $165.42 million. Tevogen Bio has a price to earnings ratio (PE ratio) of 37.59.

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is included in the company’s total 165 million outstanding...

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities.Tevogen Bio plans to...

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

WARREN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc (‘Tevogen Bio’) (Nasdaq: TVGN), a clinical-stage biotech company, announces the appointment of Tapan V Shah as Head of...

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf...

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment...

Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita

Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director of Risk Advisory Services at Verita CSG, Inc., a...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

Tevogen Bio Holdings – Tevogen (Nasdaq: TVGN) Chief Information Officer and Head of company’s Artificial Intelligence Initiative, Tevogen.ai, Mittul Mehta, has taken strides to emphasize the...

Form SC 13D - General statement of acquisition of beneficial ownership

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.18	-54.6296296296	2.16	2.16	0.803	212447	1.39623826	CS
4	-2.81	-74.1424802111	3.79	4.78	0.803	1172517	3.22415902	CS
12	-3.12	-76.0975609756	4.1	21.09	0.803	468745	3.37122917	CS
26	-3.12	-76.0975609756	4.1	21.09	0.803	468745	3.37122917	CS
52	-3.12	-76.0975609756	4.1	21.09	0.803	468745	3.37122917	CS
156	-3.12	-76.0975609756	4.1	21.09	0.803	468745	3.37122917	CS
260	-3.12	-76.0975609756	4.1	21.09	0.803	468745	3.37122917	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M